Clinical Trials
32 trialsNCT03758287 2026-05-12
Ningetinib (CT053PTSA) Plus Gefitinib in Stage IIIB or IV NSCLC Patients With EGFR Mutation and T790M Negative
Sunshine Lake Pharma Co., Ltd.
Phase 1/2 Completed
NCT03122717 2026-04-29
Osimertinib and Gefitinib in EGFR Inhibitor naïve Advanced EGFR Mutant Lung Cancer
Dana-Farber Cancer Institute
Phase 1/2 Active not recruiting
NCT06071013 2025-01-23
Nintedanib Plus EGFR TKI In EGFR-mutated Non-small Cell Lung Cancer Patients
China Medical University Hospital
Phase 1/2 Recruiting
NCT01513174 2024-06-28
GOAL
Spanish Lung Cancer Group
Phase 1/2 Completed
NCT01982955 2022-11-08
Tepotinib With Gefitinib in Participants With Locally Advanced or Metastatic NSCLC (INSIGHT)
Merck KGaA, Darmstadt, Germany
Phase 1/2 Completed
NCT02039674 2022-11-08
MK-3475-021
Merck Sharp & Dohme LLC
Phase 1/2 Completed
NCT00317772 2022-02-07
Topotecan and Gefitinib (Iressa) for Ovarian, Peritoneal, or Fallopian Tube Cancer
M.D. Anderson Cancer Center
Phase 1/2 Completed
NCT00052208 2020-10-30
Gefitinib and Radiation Therapy in Treating Patients With Glioblastoma Multiforme
National Cancer Institute (NCI)
Phase 1/2 Completed
NCT00086957 2017-02-27
Gefitinib, Trastuzumab, and Docetaxel in Treating Patients With Metastatic Breast Cancer
City of Hope Medical Center
Phase 1/2 Completed
NCT02906163 2016-09-19
First Line Bio-immunotherapy With Thymosin Alpha 1 in Patients With Sensitizing EGFR Mutation Positive Non Small Cell Lung Cancer Who Are Taking Standard of Care Therapy
SciClone Pharmaceuticals
Phase 1/2 Unknown
NCT00096486 2016-01-21
Gefitinib and Everolimus in Treating Patients With Stage IIIB or Stage IV or Recurrent Non-Small Cell Lung Cancer
Memorial Sloan Kettering Cancer Center
Phase 1/2 Completed
NCT00085566 2016-01-20
Everolimus and Gefitinib in Treating Patients With Progressive Glioblastoma Multiforme or Progressive Metastatic Prostate Cancer
Memorial Sloan Kettering Cancer Center
Phase 1/2 Completed
NCT00062270 2015-10-08
Neoadjuvant Chemoradiotherapy With or Without Gefitinib in Treating Patients With Stage IIIA or Stage IIIB Non-Small Cell Lung Cancer
University of Alabama at Birmingham
Phase 1/2 Completed
NCT00093652 2015-10-06
Oxaliplatin, Gefitinib, and Radiation Therapy in Treating Patients With Locally Advanced or Metastatic Esophageal Cancer
Roswell Park Cancer Institute
Phase 1/2 Terminated
NCT01039948 2015-04-08
A Phase 1b/2 Study in Asian Subjects With Non-Small Cell Lung Cancer
AVEO Pharmaceuticals, Inc.
Phase 1/2 Completed
NCT00042991 2014-05-28
Gefitinib and Radiation Therapy in Treating Children With Newly Diagnosed Gliomas
National Cancer Institute (NCI)
Phase 1/2 Completed
NCT00423397 2013-12-19
Gefitinib and PEG-Interferon Alfa-2a in Treating Patients With Unresectable or Metastatic Skin Cancer
National Cancer Institute (NCI)
Phase 1/2 Unknown
NCT00809237 2013-12-10
Hydroxychloroquine and Gefitinib to Treat Lung Cancer
National University Hospital, Singapore
Phase 1/2 Unknown
NCT00026299 2013-09-05
Oxaliplatin With or Without Gefitinib in Treating Patients With Metastatic or Locally Recurrent Colorectal Cancer
University of Chicago
Phase 1/2 Completed
NCT00268255 2013-04-16
Gefitinib and Radiation Therapy in Treating Patients With Inoperable Stage I or Stage II Non-Small Cell Lung Cancer
Barbara Ann Karmanos Cancer Institute
Phase 1/2 Withdrawn
NCT00087334 2013-02-01
Capecitabine, Oxaliplatin, and Gefitinib in Treating Patients With Metastatic Colorectal Cancer
Roswell Park Cancer Institute
Phase 1/2 Terminated
NCT00352105 2012-11-05
Cisplatin, Fluorouracil, Iressa, and Radiation Therapy Patients With Locally Advanced Head and Neck Cancer
Case Comprehensive Cancer Center
Phase 1/2 Completed
NCT00098462 2012-10-04
Gefitinib and Sirolimus in Treating Patients With Recurrent or Refractory Stage IIIB or Stage IV Non-Small Cell Lung Cancer
Jonsson Comprehensive Cancer Center
Phase 1/2 Withdrawn
NCT00212108 2012-04-02
A Study Of Nasopharyngeal Carcinoma (NPC) Treated With Celecoxib And ZD1839
National University Hospital, Singapore
Phase 1/2 Completed
NCT00113529 2011-08-29
Study Of SU011248 Plus Gefitinib (Iressa) In Patients With Advanced Renal Cell Carcinoma
Pfizer
Phase 1/2 Completed
NCT00238628 2010-07-20
A Phase I/II Study of Bexarotene in Combination With ZD1839 (IRESSA®) in the Treatment of Non-Small Cell Lung Cancer
Stanford University
Phase 1/2 Completed
NCT00234416 2009-04-23
IRESSA Combined With Radiotherapy & Gemcitabine as First-Line Treatment in Locally Advanced Pancreatic Cancer
AstraZeneca
Phase 1/2 Completed
NCT00237900 2009-04-23
Gefitinib in Combination With Chemoradiation in Resectable Gastric Cancer
AstraZeneca
Phase 1/2 Terminated
NCT00239291 2009-04-23
Safety Study to Explore Combination of Gefitinib (ZD1839, Iressa) and Radiotherapy in Non-Metastatic Prostate Cancer
AstraZeneca
Phase 1/2 Completed
NCT00242788 2009-04-23
IRESSAâ„¢ In Combo With Xelodaâ„¢ in Advanced Colorectal Cancer Patients After 1st-Line Chemo Failure
AstraZeneca
Phase 1/2 Completed
NCT00239304 2007-12-18
Gefitinib (Iressa) in Combo With Chemoradiation in Patients With Locally Advanced Head & Neck Cancer
AstraZeneca
Phase 1/2 Completed
NCT00195078 2007-07-20
Safety Trial of IRESSA, Cisplatin and Radiation Therapy for Patients With Head and Neck Cancer
Weill Medical College of Cornell University
Phase 1/2 Terminated